Acetyl-L-Carnitine Research & Evidence

SupplementScience.ai Editorial Team·Evidence-Based Supplement Research

Published Mar 11, 2026

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Moderate

ALCAR has a substantial clinical evidence base, particularly for age-related cognitive decline. Montgomery et al. (2003) meta-analyzed 21 RCTs and found significant cognitive improvements in MCI and early Alzheimer's patients. Veronese et al. (2018) conducted a landmark meta-analysis showing ALCAR is comparable to standard antidepressants for depression with fewer side effects. The Ames laboratory pioneered research showing ALCAR + alpha-lipoic acid rejuvenates mitochondrial function in aged animals, though human translation of these findings is still developing.

Evidence by Condition

Condition	Studied Dose	Evidence
Cognitive enhancement	500-1500mg daily	Moderate
Depression (adjunct)	1000-3000mg daily	Moderate
Age-related cognitive decline	1500-2000mg daily	Moderate
Neuropathic pain	1500-3000mg daily	Moderate

Full Acetyl-L-Carnitine Guide

References

Montgomery SA, Thal LJ, Amrein R (2003). Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology. DOI PubMed
Veronese N, Stubbs B, Solmi M, et al. (2018). Acetyl-L-Carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis. Psychosomatic Medicine. DOI PubMed
Ames BN, Liu J (2004). Delaying the mitochondrial decay of aging with acetylcarnitine. Annals of the New York Academy of Sciences. DOI PubMed